An Australian startup with Researchers as Founders

Founded in 2015 by the inventors of the technology, BTR’s mission is to transform the diagnosis of major diseases to reduce mortality and morbidity globally and lower the cost of health care worldwide. 

Our diagnostic platform has been developed at the Monash Centre for Biospectroscopy in Melbourne Australia and is protected by international patent filings. 

It is a true point of care diagnostic system that is rapid, sensitive and specific and more cost-effective than current technologies and systems. The diagnostic process requires minimal training and does not rely on chemical reagents, microscopy or other laboratory-based skills to diagnose infectious disease.  It has the potential to transform large parts the diagnostics industry worldwide. 

BTR has a proof of concept with validated data for the diagnosis of a range of pathogens including; parasites (malaria, babesia), viruses (HVC & HBC), fungal and bacterial blood stream infections that cause sepsis.

Trials of our technology have been conducted in Australia by The Alfred Hospital, Monash Health and the Victorian Infectious Diseases Reference Laboratory (VIDRL) and internationally with Khon Kaen University in Thailand and Institut Pasteur in Laos. 

BTR’s initial product will be the world’s first rapid, point of care diagnosis of the pathogens that cause sepsis, a condition that kills more than 6 million people around the world each year. The estimated addressable market for BTR’s blood stream infection diagnostic is USD 2.4 billion per annum.